SCHEMBL8725928

SCHEMBL8725928

O=C(Nc1ccc2scc(C3CCC4CCCCN4CC3)c2c1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.47
KMT2A Q03164 2/20 0.43
TP53 P04637 2/20 0.42
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
HRH3 Q9Y5N1 3/20 0.41
HTR1D P28221 2/20 0.39
HTR1A P08908 1/20 0.39
HTR1B P28222 1/20 0.39
HTR1F P30939 1/20 0.39
HSD11B1 P28845 2/20 0.39
HSD17B1 P14061 1/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
L3MBTL3 Q96JM7 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8723856 0.91 HTR1D (0.50) TP53MAPK1HRH3HTR1DHTR1A
SCHEMBL8724094 0.89 ACKR3 (0.39) RORCKMT2ATDP1HRH3HTR1D
SCHEMBL8720774 0.89 L3MBTL3 (0.43) RORCHRH3HTR1DHTR1AHTR1B
SCHEMBL30909070 0.88 TDP1 (0.38) RORCKMT2AMAPTTDP1MEN1
SCHEMBL8721187 0.88 TDP1 (0.38) RORCKMT2AMAPTTDP1MEN1
Fumaric Acid SCHEMBL8725912 0.88 HTR1D (0.46) MAPTHRH3HTR1DHTR1AHTR1B
Fumaric Acid SCHEMBL8725918 0.88 HTR1D (0.46) MAPTHRH3HTR1DHTR1AHTR1B
SCHEMBL8721836 0.88 TMIGD3 (0.41) RORCTDP1HRH3HTR1DHTR1A
SCHEMBL8723596 0.88 ALDH1A1 (0.44) KMT2ATP53MAPTTDP1MEN1
SCHEMBL30908934 0.88 ALDH1A1 (0.44) KMT2ATP53MAPTTDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D RORC 1266/4885KMT2A 2708/4885TP53 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.